← Leaderboards
S Vincent Rajkumar
Mayo Clinic Coll Of Medicine, Rochester
$8,690,866
Attributed
$11,114,442
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $798.3K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,114,442 · 6
By mechanism
R01$9,772,487 · 4
P01$1,059,755 · 1
R21$282,200 · 1
Top collaborators
- Shaji Kunnathu Kumar16 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Diane F Jelinek$8,218,570
- Celine M Vachon$17,209,085
- Robert A Kyle$833,522
- Joseph A Murray$9,616,112
- Rafael Fonseca$16,992,958
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaMalignant NeoplasmsMarrowMonoclonal Gammopathy Of Uncertain SignificancePlasma CellsFirst Degree RelativePremalignantRisk FactorsLifeLaboratoriesPrevalenceSamplingMonoclonal GammapathiesFlow CytometryBone MarrowBaseIncidenceDiagnosisGrantLesionPreventPopulation BasedPredispositionCohort
Grant awards (40)
Onset and biomarkers for progression of monoclonal gammopathies$78,948
R01 · FY2024 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$414,033
R01 · FY2023 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$434,502
R01 · FY2022 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$94,779
R01 · FY2021 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$217,458
R01 · FY2020 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$377,625
R01 · FY2019 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2018 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2017 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2016 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2016 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2015 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2015 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$321,975
R01 · FY2014 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$320,027
R01 · FY2014 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$310,130
R01 · FY2013 · CA · contact PI
Prevalance and Progression of Monoclonal Gammopathies$275,835
R01 · FY2013 · CA · contact PI
Onset and biomarkers for progression of monoclonal gammopathies$329,925
R01 · FY2012 · CA · contact PI
Prevalance and Progression of Monoclonal Gammopathies$293,441
R01 · FY2012 · CA · contact PI
Prevalance and Progression of Monoclonal Gammopathies$293,441
R01 · FY2011 · CA · contact PI
Prevalance and Progression of Monoclonal Gammopathies$302,516
R01 · FY2010 · CA · contact PI
Prevalance and Progression of Monoclonal Gammopathies$302,516
R01 · FY2009 · CA · contact PI
Epidemiology of MGUS in Southeastern Minnesota$261,778
P01 · FY2009 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$286,707
R01 · FY2008 · CA · contact PI
Epidemiology of MGUS in Southeastern Minnesota$202,590
P01 · FY2008 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$286,707
R01 · FY2007 · CA · contact PI
Epidemiology of MGUS in Southeastern Minnesota$191,505
P01 · FY2007 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$295,270
R01 · FY2006 · CA · contact PI
Treatment of Early Stage Multiple Myeloma$257,207
R01 · FY2006 · CA · contact PI
Epidemiology of MGUS in Southeastern Minnesota$204,925
P01 · FY2006 · CA · contact PI
Prevalence and Progression of Monoclonal Gammopathies$302,375
R01 · FY2005 · CA
Treatment of Early Stage Multiple Myeloma$296,997
R01 · FY2005 · CA
Epidemiology of MGUS in Southeastern Minnesota$198,957
P01 · FY2005 · CA
Prevalence and Progression of Monoclonal Gammopathies$302,375
R01 · FY2004 · CA
Treatment of Early Stage Multiple Myeloma$296,430
R01 · FY2004 · CA
Angiogenesis and thalidomide therapy in multiple myeloma$279,135
R01 · FY2004 · CA
Treatment of Early Stage Multiple Myeloma$287,083
R01 · FY2003 · CA
Angiogenesis and thalidomide therapy in multiple myeloma$278,818
R01 · FY2003 · CA
Angiogenesis and thalidomide therapy in multiple myeloma$288,482
R01 · FY2002 · CA
ANGIOGENESIS AND ANGIOGENIC CYTOKINES IN MYELOMA$141,100
R21 · FY2001 · CA
ANGIOGENESIS AND ANGIOGENIC CYTOKINES IN MYELOMA$141,100
R21 · FY2000 · CA